CTI BioPharma blood cancer drug meets study goal

(Reuters) – CTI BioPharma Corp said its experimental blood cancer treatment achieved the main goal of a late-stage study.

Data from the study showed that the drug, pacritinib, was significantly better than the “best available therapy” as prescribed by the patients’ physician to treat myelofibrosis.

Myelofibrosis is a form of blood cancer that makes the bone marrow produce too much of any type of blood cells.

(Reporting by Vidya L Nathan in Bengaluru; Editing by Savio D’Souza)

• Health
• Disease Medical Conditions
• blood cancer